THERAPEUTICS
Review: little high-quality evidence is available regarding treatments for localised prostate cancer
| The first 150 words of the full text of this article appear below. |
T J Wilt
Dr T J Wilt, University of Minnesota School of Medicine, Minneapolis, MN, USA; tim.wilt@med.va.gov
QUESTION
In men with localised prostate cancer, what is the evidence for effectiveness and harm of various treatments?
REVIEW SCOPE
Included studies evaluated treatments for localised prostate cancer (tumour stage T1 or T2). Outcomes were all-cause and disease-related mortality, biochemical and clinical progression, and adverse events.
REVIEW METHODS
Cochrane Library (Issue 3, 2007) and Cochrane Review Group in Prostate Diseases and Urologic Malignancies specialised register (Nov 2007) were searched for randomised controlled trials (RCTs). Other sources were searched for observational studies. 18 RCTs (n = 6482, mean age 63–73 y, mean follow-up 3–23 y), 1 pooled analysis of 3 RCTs (n = 8113, mean age 67 y, median follow-up 5.4 y), and 473 observational studies met the selection criteria.
MAIN RESULTS
The table shows results for all-cause mortality in RCTs comparing different treatments. Death from prostate cancer was reduced with
New Mexico VA Health Care Center, Albuquerque, New Mexico, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
